Close

The BIO International Convention Closes after Four “Breakthrough” Days in San Diego

Jun 22 2017
The 2017 BIO International Convention  (BIO 2017), hosted by the Biotechnology Innovation Organizatio (BIO), closed today after four days of immersive, compelling programming united under the theme of “Breakthrough.”  BIO 2017 recognized past, present and future biotech breakthroughs that heal, feed and fuel the world

BIO Expands Cooperation with China-Based Pharma Group

Jun 22 2017
Memorandum of Understanding for Cooperation continues the longstanding relationship between BIO and RDPAC and deepens our cooperative efforts.

BIO Statement of Support for the Introduction of the STRONGER Patents Act of 2017

Jun 21 2017
Bill cracks down on false or deceptive patent demand letters, ensures urgently-needed fairness and finality in Patent Office post grant proceedings, eliminates diversion of PTO user fees, and helps American research-intensive companies protect their investments in innovation

New Report: Licensing of Academic Patents Has Contributed Up to $1.3 Trillion to US Economy

Jun 20 2017
Tech Transfer Has Supported Up to 4.2 Million Jobs Since 1996

BIO Releases Bioscience Economic Development Guide

Jun 20 2017
At the 2017 BIO International Convention, cabinet-level appointees representing Texas, Massachusetts, Rhode Island, and Puerto Rico participated in the report's release by discussing bioscience industry economic development and state policies that have proven successful in assisting industry growth.

America Must Strengthen Bioscience Innovation Leadership

Jun 20 2017
Regulatory Systems Must Be Consistent across Agencies and Based on Actual Risk   Washington, D.C. (June 20, 2017) – In comments submitted to the U.S. Depart of Agriculture (USDA) and U.S. Food and Drug Administration (FDA), the Biotechnology Innovation Organization (BIO) urges the Administration to take consistent and decisive steps to unleash the full potential of American bio-based innovation in food, feed, agriculture, and animal health. Doing so will reinforce the United States’ global leadership in these sectors and foster the creation of more well-paying jobs at innovative companies throughout the country.

BIO Adopts Principles on Workplace Development, Diversity, and Inclusion; Launches Board WDDI Committee

Jun 19 2017
Washington, DC (June 19, 2017) – Today, the Biotechnology Innovation Organization (BIO) released a set of principles on workforce development, diversity, and inclusion (WDDI) for the biotechnology industry.  Concurrent with the adoption of these principles, BIO established a board-level WDDI Committee charged with working to foster workforce development, diversity, and inclusion at BIO and throughout the biotech industry.  The Committee will be chaired by Helen Torley, President & CEO of Halozyme, who is succeeding Julie Gerberding, Executive Vice President & Chief Patient Officer at Merck, who led the Committee as it developed BIO’s WDDI principles over the last year.

BIO Elects John Maraganore, Ph.D., as New Chair

Jun 19 2017
A new slate of officers and Board members were elected during the 2017 BIO International Convention.

Media Advisory: Bioscience Job Creation Through Smart State Policies

Jun 16 2017
Release of report detailing state legislative best practices in support of bioscience jobs, investments and innovation.

Media Advisory: University Research is Key Driver of National Economy

Jun 16 2017
New report demonstrates the enormous financial and jobs impact from patent licensing of university research, known as tech transfer. Real-world examples of success from the University of California System and Stanford University will be shared.